U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982352) titled 'Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis' on May 13.
Brief Summary: The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered as an oral solution for 28 days.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Psoriasis (PsO)
Intervention:
DRUG: LPX-TI641
Oral solution administered QD...